What the data shows
Worldpanel by Numerator said on Thursday that appetite-reducing GLP-1 drugs are pulling down grocery demand, including for snacks like potato chips. Looking at the year after treatment starts, households with a GLP-1 user purchased 415 million fewer food items. That reduction is larger than the roughly 300 million decline noted when the tracker was last released in June.
The firm estimates more than one in ten households will include a GLP-1 user by 2027. It says the current share is 8.5%, about the same as the combined footprint of vegetarian and pescatarian households.
How retailers are reacting
"This is not a flash-in-the-pan trend, but a seismic change that requires retailers and manufacturers to rethink their strategies," according to Chantel Kennaugh, who leads public sector and nutrition at Worldpanel. Supermarkets including Morrisons and Tesco Plc have rolled out smaller, protein-focused meals for GLP-1 customers, while Boots has added products centered on digestive health.
Where the money is going
Some of the saved grocery cash is showing up in other categories such as clothing and footwear. The study additionally concluded that, within health and beauty, GLP-1 users spent £78 million above Worldpanel's forecast.
When shopping habits shift, staying informed matters, so sign up for the free Market Briefs newsletter for quick daily clarity
Why does that matter? Spending mix is shifting. Supermarkets experimenting with portion size and protein content, apparel retailers, and health and beauty chains could see different tailwinds and headwinds as GLP-1 adoption grows.
Because small consumer changes can add up, get concise context each morning with Market Briefs, our free daily newsletter
